These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7986930)

  • 1. Effectiveness of amphotericin B in lipid emulsion for treating fungal septicemia in granulocytopenic patients.
    Macedo MC; Dulley FL; Ostronoff M; Machado CM; Zambon E; Matsumoto C; Dorlhiac-Llaccer P; Chamone DF
    Clin Infect Dis; 1994 Aug; 19(2):366-7. PubMed ID: 7986930
    [No Abstract]   [Full Text] [Related]  

  • 2. Breakthrough fungemia caused by Candida stellatoidea in a patient with lymphoma associated with shock, successfully treated with amphotericin B lipid complex.
    Sufliarsky J; Sorkovska D; Kunova A; Helpianska L; Krcméry V
    Infection; 1995; 23(4):246-7. PubMed ID: 8522386
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment with liposomal amphotericin B in two patients with persisting fungemia.
    Sculier JP; Bron D; Coune A; Meunier F
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):903-7. PubMed ID: 2512139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits.
    Chavanet P; Duong M; Buisson M; Hamel H; Dubois C; Bonnin A; Portier H
    J Antimicrob Chemother; 1997 Mar; 39(3):427-30. PubMed ID: 9096196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fungal infections complicating acute leukemia.
    Bodey GP
    J Chronic Dis; 1966 Jun; 19(6):667-87. PubMed ID: 5229422
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of a Trichosporon beigelii septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor.
    Grauer ME; Bokemeyer C; Bautsch W; Freund M; Link H
    Infection; 1994; 22(4):283-6. PubMed ID: 7528173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and treatment of fungal infections in neutropenic patients.
    von Paleske A; Müllerleile U; Gressler V; Garbrecht M; Hossfeld DK
    Haematol Blood Transfus; 1987; 30():545-6. PubMed ID: 3476385
    [No Abstract]   [Full Text] [Related]  

  • 8. Epidemiological characteristics of fatal Candida krusei fungemia in immunocompromised febrile neutropenic children.
    Agirbasli H; Otlu B; Bilgen H; Durmaz R; Gedikoglu G
    Infection; 2008 Feb; 36(1):88-91. PubMed ID: 18084719
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficacy of two different lipid-based amphotericin B in neonatal Candida septicemia.
    Cetin H; Yalaz M; Akisu M; Hilmioglu S; Metin D; Kultursay N
    Pediatr Int; 2005 Dec; 47(6):676-80. PubMed ID: 16354223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis.
    Walsh TJ; Aoki S; Mechinaud F; Bacher J; Lee J; Rubin M; Pizzo PA
    J Infect Dis; 1990 Apr; 161(4):755-60. PubMed ID: 2138654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin.
    Olver WJ; Scott F; Shankland GS
    Med Mycol; 2006 Nov; 44(7):655-7. PubMed ID: 17071561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida arthritis treated with amphotericin B.
    Poplack DG; Jacobs SA
    J Pediatr; 1975 Dec; 87(6 Pt 1):989-90. PubMed ID: 1059760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow response of invasive Candida krusei infection to amphotericin B in a clinical time-kill study.
    Majoros L; Szegedi I; Kardos G; Erdész C; Kónya J; Kiss C
    Eur J Clin Microbiol Infect Dis; 2006 Dec; 25(12):803-6. PubMed ID: 17058066
    [No Abstract]   [Full Text] [Related]  

  • 14. Failure of a lipid amphotericin B preparation to eradicate candiduria: preliminary findings based on three cases.
    Agustin J; Lacson S; Raffalli J; Aguero-Rosenfeld ME; Wormser GP
    Clin Infect Dis; 1999 Sep; 29(3):686-7. PubMed ID: 10530471
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent developments in prophylaxis and therapy of invasive fungal infections in granulocytopenic cancer patients.
    Meunier F; Klastersky J
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):539-44. PubMed ID: 3383960
    [No Abstract]   [Full Text] [Related]  

  • 16. Administration of amphotericin B in lipid emulsion.
    O'Neil MG; Lapointe M
    Crit Care Med; 1997 May; 25(5):892-3; author reply 893-4. PubMed ID: 9187614
    [No Abstract]   [Full Text] [Related]  

  • 17. Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia.
    Myoken Y; Kyo T; Kohara T; Fujihara M; Sugata T; Mikami Y
    Clin Infect Dis; 2003 Jun; 36(11):1496-7. PubMed ID: 12766847
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of caspofungin and amphotericin B for invasive candidiasis.
    Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
    N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluconazole therapy in a child with Candida tropicalis fungemia.
    Santeiro ML; Riggs D; Weibley RE
    Ann Pharmacother; 1992 Jun; 26(6):840-1. PubMed ID: 1611170
    [No Abstract]   [Full Text] [Related]  

  • 20. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.
    Kirsh R; Goldstein R; Tarloff J; Parris D; Hook J; Hanna N; Bugelski P; Poste G
    J Infect Dis; 1988 Nov; 158(5):1065-70. PubMed ID: 3183418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.